These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 28301705)

  • 21. Resistance to antibiotics: are we in the post-antibiotic era?
    Alanis AJ
    Arch Med Res; 2005; 36(6):697-705. PubMed ID: 16216651
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?
    Wellman-Labadie O; Zhou Y
    Health Policy; 2010 May; 95(2-3):216-28. PubMed ID: 20036435
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pathways across the valley of death: novel intellectual property strategies for accelerated drug discovery.
    Rai AK; Reichman JH; Uhlir PF; Crossman C
    Yale J Health Policy Law Ethics; 2008; 8(1):1-36. PubMed ID: 18564492
    [No Abstract]   [Full Text] [Related]  

  • 24. Industry reneges on postmarketing trial commitments.
    Bouchie A
    Nat Biotechnol; 2003 Jul; 21(7):718. PubMed ID: 12833074
    [No Abstract]   [Full Text] [Related]  

  • 25. Clinical research and the development of new drugs: issues for nurses.
    Holaday B; Mills DM
    Dimens Crit Care Nurs; 2004; 23(4):179-86. PubMed ID: 15273487
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Congress Considers Legislation on "21st Century Cures".
    Consult Pharm; 2015 Jul; 30(7):424. PubMed ID: 26173195
    [No Abstract]   [Full Text] [Related]  

  • 27. Development of new antibiotics: taking off finally?
    Bettiol E; Harbarth S
    Swiss Med Wkly; 2015; 145():w14167. PubMed ID: 26230280
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cutting red tape to manage public health threats: An ethical dilemma of expediting antibiotic drug innovation.
    Munthe C; Nijsingh N
    Bioethics; 2019 Sep; 33(7):785-791. PubMed ID: 31222764
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Forging a new path. New law offers incentives to develop antibiotics.
    Lee J
    Mod Healthc; 2013 Feb; 43(5):8-9. PubMed ID: 23437480
    [No Abstract]   [Full Text] [Related]  

  • 30. Unapproved drugs in the United States and the Food and Drug Administration.
    Nasr A; Lauterio TJ; Davis MW
    Adv Ther; 2011 Oct; 28(10):842-56. PubMed ID: 21894470
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Desperately seeking cancer drugs: explaining the emergence and outcomes of accelerated pharmaceutical regulation.
    Davis C; Abraham J
    Sociol Health Illn; 2011 Jul; 33(5):731-47. PubMed ID: 21314687
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Pediatric drug development: ICH harmonized tripartite guideline E11 within the United States of America, the European Union, and Japan].
    Pflieger M; Bertram D
    Arch Pediatr; 2014 Oct; 21(10):1129-38. PubMed ID: 25175054
    [TBL] [Abstract][Full Text] [Related]  

  • 33. American Society of Clinical Oncology policy statement: oversight of clinical research.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2377-86. PubMed ID: 12721281
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Perestroika in pharma: evolution or revolution in drug development?
    FitzGerald GA
    Mt Sinai J Med; 2010; 77(4):327-32. PubMed ID: 20687177
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America.
    Spellberg B; Guidos R; Gilbert D; Bradley J; Boucher HW; Scheld WM; Bartlett JG; Edwards J;
    Clin Infect Dis; 2008 Jan; 46(2):155-64. PubMed ID: 18171244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Regulatory challenges in the review of data from global clinical trials: the PMDA perspective.
    Asano K; Tanaka A; Sato T; Uyama Y
    Clin Pharmacol Ther; 2013 Aug; 94(2):195-8. PubMed ID: 23872835
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmaceutical lobbying in Brazil: a missing topic in the public health research agenda.
    Paumgartten FJ
    Rev Saude Publica; 2016 Dec; 50():70. PubMed ID: 28099661
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Target small firms for antibiotic innovation.
    Hwang TJ; Carpenter D; Kesselheim AS
    Science; 2014 May; 344(6187):967-9. PubMed ID: 24876477
    [No Abstract]   [Full Text] [Related]  

  • 39. Systems, not pills: The options market for antibiotics seeks to rejuvenate the antibiotic pipeline.
    Brogan DM; Mossialos E
    Soc Sci Med; 2016 Feb; 151():167-72. PubMed ID: 26808335
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intellectual property. Fixing the legal framework for pharmaceutical research.
    Knowles SM
    Science; 2010 Feb; 327(5969):1083-4. PubMed ID: 20150445
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.